ClinicalTrials.gg
RecruitingNCT06630585AID-JUNCTUpdated Jan 26, 2026

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

A Phase 3 interventional study of Tirzepatide in Type 1 Diabetes (T1D), sponsored by University of Bern. Recruiting at 3 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by University of Bern · Phase 3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.

Planned enrollment
22nd of 52
42 · median 29
Started
2025
with 3 others
Phase 3
13 of 70
3 open now
Registered
64th of 70
by date
Lead sponsor
2 of 70
University of Bern

Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 22nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 in phase 3, and was the 64th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, or all of them as a file.
02

Study summary

Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D.

This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.

Read the detailed description

Glycemic control in type 1 diabetes (T1D) remains a challenge, with \~30% of adults achieving an A1c target of 7%. The glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as a promising therapy in T1D. Retrospective studies have shown patients with T1D can significantly improve glycemic control with a reduction in insulin dose and body weight when long-acting GLP-1RAs or GIP/GLP-1RAs are added to insulin therapy. However, randomized controlled trials (RCT) are still lacking.

This is a prospective, randomized, open-label design. The investigators will enroll 42 participants over 18 years of age with confirmed T1D diagnosis ≥6 months, currently on automatic insulin delivery (AID) therapy for at least three months, with A1C ≥6.5% and ≤10%and BMI ≥23 kg/m2. Participants will be randomized in a 1:1 ratio to either tirzepatide 5.0 mg or continue with the Standard of Care (SoC) for 12 weeks (after a titration phase with the lowest dose of 2.5 mg). The primary endpoint is continuous glucose monitoring (CGM) percent time spent between 3.9 and 10.0 mmol/L (TIR) from baseline to follow-up after 12 weeks of treatment. Secondary endpoints include the change in 24/7 CGM percent time \>10.0 mmol/L, 24/7 CGM percent time \>13.9 mmol/L, 24/7 CGM percent time \<3.9 mmol/L, 24/7 CGM percent time \<3.0 mmol/L and the change in body mass index (BMI).

This is the first prospective study to investigate the efficacy and safety of tirzepatide (GIP/GLP1-RAs) as an adjuvant therapy to AID. This study may contribute unique data to significantly improving glucose outcomes, reducing the T1D burden, improving the quality of life, and re-directing attention to further treatment in T1D beyond insulin therapies.

03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • Type 1 diabetes
  • Adjuvant therapy
  • Incretins
  • GIP/GLP-1RA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with diagnosed T1D for at least 12 months.
  2. Aged between 18 to 65 years old (inclusive).
  3. Currently on AID therapy for at least three months.
  4. higher or equal to 6.5% and less or equal to 10%.
  5. ≥23 kg/m2.
  6. Willing to use once-weekly tirzepatide for at least 16 weeks (including four weeks of up-titration and 12 weeks of treatment)
  7. Willing to wear a Dexcom G7 Sensor and share devices (AID) data uploads.
  8. Willingness not to start any new non-insulin glucose-lowering agent during the trial (including metformin/biguanides, pramlintide, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors [SGLT2 inhibitors], and nutraceuticals).
  9. A stable weight (± 5%) in the last 90 days or more before the screening and agree to not initiate a diet and/or exercise program during the study to reduce body weight other than the lifestyle and dietary measures for diabetes treatment.
  10. Females with and males (if apply) must be willing to use reliable methods (for the contraceptives study guidelines. See Annex 7 of the protocol)
  11. An understanding and willingness to follow the protocol and signed .

Exclusion criteria

Exclusion Criteria:

  1. History of diabetic ketoacidosis requiring hospitalization in the past six months.
  2. History of severe hypoglycemic event (Level 3, defined as seizure or loss of consciousness) in the past six months.
  3. Uncontrolled Diabetic retinopathy or maculopathy
  4. Severe gastroparesis.
  5. Less than 12 months of insulin treatment.
  6. Estimated (eGFR) lab value below 30 mL/min/1.73 m2 by the CKD-EPI formula(99).
  7. Pregnancy or intention to become pregnant during the trial (See annex 7).
  8. Currently breastfeeding or planning to breastfeed.
  9. Currently uncontrolled seizure disorder.
  10. History of allergy to GIP/GLP-1RAs or its .
  11. Personal or family history of multiple endocrine neoplasia type 2 (MEN-2) or medullary thyroid carcinoma.
  12. Screening calcitonin above or equal to 35 ng/L.
  13. Planned any surgery during the study duration.
  14. Have uncontrolled hypertension (systolic BP above or equal to 160 mmHg and/or diastolic BP above or equal to 100 mmHg). If a participant is on anti-hypertensive therapies, doses must be stable for 30 days before screening. For participants with uncontrolled hypertension at the screening visit, antihypertensive medication may be started or adjusted.
  15. Personal history of one of the following cardiovascular conditions (within two months before the screening): acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF).
  16. Conditions that may increase the risk of induced hypoglycemia, such as CHF with Functional Classification III or IV or adrenal insufficiency.
  17. Have a history of documented (HIV) infection.
  18. Have an uncontrolled cardiac arrhythmia based on an (ECG) at the screening time and the investigator's discretion.
  19. Cystic fibrosis.
  20. Patient with a history of gastric bypass (bariatric) surgery, sleeve gastrectomy, or restrictive bariatric surgery, such as Lap-Band® or gastric banding.
  21. Uncontrolled thyroid disease as judged by the investigator
  22. Serum triglycerides higher than 5.7 mmol/L (500 mg/dL) at the screening. If a participant is on lipid-lowering therapies, doses must be stable for 30 days before screening.
  23. Personal history of acute or chronic pancreatitis. A participant with a history of acute pancreatitis caused by gallstones may be included in the study if the participant has had a cholecystectomy to resolve the problem.
  24. Acute or chronic hepatitis other than MASLD.
  25. Have a history of symptomatic gallbladder disease within the past two years (unless the participant has had a cholecystectomy to resolve the problem).
  26. History of requiring chemotherapy, surgery, or radiation (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) in the previous five years.
  27. Active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (such as known drug or alcohol abuse, diagnosed eating disorder, or any other uncontrolled psychiatric disorder) that, in the investigator's opinion, may preclude the participant from following and completing the protocol.
  28. Treatment with non-insulin glucose-lowering agents other than metformin (on a stable dose 30 days before the study)
  29. Weight loss medications in the past three months.
  30. Participants who are anticipated to receive, are receiving, or have received within three months before the screening (more than two weeks and more or equal to 10mg prednisolone-equivalent) chronic systemic therapy (excluding topical, intraocular, intranasal, single intraarticular injection, or inhaled preparations).
  31. Have current treatment with (or history of, within three months before screening) medications that may significantly affect glucose metabolism.
  32. Use of drugs within five half-lives before screening.
  33. Participation in another study with an investigational drug within the 30 days preceding and during the present study.
  34. Current enrollment in another clinical trial unless approved by the investigator of both studies and if the clinical trial is a non-interventional registry trial.
  35. Have evidence of a significant active, uncontrolled medical condition or a history of any medical problem capable of constituting a risk when using the study devices or interfering with following study procedures or the interpretation of data, as judged by the study physician at screening.
  36. The enrolment of the investigator, his/her family members, employees, and other dependent persons.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Participants in this arm will use their standard of care (SoC)

  • Experimental
    Standard of Care + Drug

    Participants in this arm will use their standard of care (SoC) plus tirzepatide (titrated to reach a minimum accepted dose.

    Drug: Tirzepatide

Interventions

  • Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial. In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks.

    Also known as: GIP/GLP-1RA

06

What researchers measure

Primary outcomes

  1. Change TIR

    Mean difference in 24/7 CGM percentage time spent between 3.9 and 10 mmol/L (TIR) between groups.

    Time frame: At week 16 of treatment.

Secondary outcomes

  1. Glycated Hemoglobin

    Mean difference between groups Glycated Hemoglobin.

    Time frame: At week 16 of treatment.

  2. CGM-measured TIR between 0700 and 2300 (TIR7-23)

    Mean difference between groups in CGM-measured TIR between 0700 and 2300 (TIR7-23).

    Time frame: At week 16 of treatment.

  3. CGM-measured time in the tight range (TTR, 3.9-7.8 mmol/L)

    Mean difference between groups in CGM-measured time in the tight range (TTR, 3.9-7.8 mmol/L).

    Time frame: At week 16 of treatment.

  4. 24/7 CGM-measured percent time >10.0 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \>10.0 mmol/L

    Time frame: At week 16 of treatment.

  5. 24/7 CGM-measured percent time >13.9 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \>13.9 mmol/L

    Time frame: At week 16 of treatment.

  6. 24/7 CGM-measured percent time <3.9 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \<3.9 mmol/L

    Time frame: at week 16 of treatment

  7. 24/7 CGM-measured percent time <3.0 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \<3.0 mmol/L

    Time frame: At week 16 of treatment.

  8. 24/7 Total Daily Insulin (TDI)

    Mean difference between in 24/7 Total Daily Insulin (TDI)

    Time frame: At week 16 of treatment.

Other outcomes

  1. CGM-measured TIR between 0700 and 2300 (TIR7-23)

    Mean difference between groups in CGM-measured TIR between 0700 and 2300 (TIR7-23).

    Time frame: At week 8, 12 and 16 of treatment.

  2. 24/7 CGM-measured percent time >10.0 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \>10.0 mmol/L

    Time frame: At week 8, 12 and 16 of treatment.

  3. 24/7 CGM-measured percent time >13.9 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \>13.9 mmol/L

    Time frame: At week 8, 12 and 16 of treatment.

  4. 24/7 CGM-measured percent time <3.9 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \<3.9 mmol/L

    Time frame: At week 8, 12 and 16 of treatment.

  5. 24/7 CGM-measured percent time <3.0 mmol/L

    Mean difference between groups in 24/7 CGM-measured percent time \<3.0 mmol/L

    Time frame: At week 8, 12 and 16 of treatment.

  6. CGM-measured glucose variability (CV)

    CGM-measured glucose variability measured with the coefficient of variation (CV)

    Time frame: At week 8, 12 and 16 of treatment.

  7. 24/7 Total Daily Insulin (TDI)

    Mean difference between in 24/7 Total Daily Insulin (TDI)

    Time frame: At week 8, 12 and 16 of treatment.

  8. 24/7 Total Daily Bolus (TDBo)

    Mean difference between in 24/7 Total Daily Bolus (TDBo)

    Time frame: At week 8, 12 and 16 of treatment.

  9. Body Weight (BW)

    Mean difference between groups in BW

    Time frame: At week 16 of treatment.

  10. Waist Circumference (WC)

    Mean difference between groups in WC

    Time frame: At week 16 of treatment

  11. Hip circumference

    Mean difference between the groups in hip circumference

    Time frame: At week 16 of treatment.

  12. Waist-to-hip ratio

    Mean difference between groups in Waist-to-hip ratio

    Time frame: At week 16 of treatment.

  13. % Fat mass

    Mean difference between groups in % fat mass

    Time frame: At week 16 of treatment.

  14. Fat mass index

    Mean difference between groups in Fat mass index

    Time frame: At week 16 of treatment.

  15. Visceral adipose tissue

    Mean difference between groups in visceral adipose tissue

    Time frame: At week 16 of treatment.

  16. Lean Mass Index

    Mean difference between groups in Lean Mass Index

    Time frame: At week 16 of treatment.

  17. Appendicular Lean Mass Index

    Mean difference between groups in Appendicular Lean Mass Index

    Time frame: At week 16 of treatment.

  18. Cholesterol LDL

    Mean difference between groups in Cholesterol LDL

    Time frame: At week 16 of treatment.

  19. Cholesterol HDL

    Mean difference between groups in Cholesterol HDL

    Time frame: At week 16 of treatment.

  20. Cholesterol non-HDL

    Mean difference between groups in cholesterol non-HDL

    Time frame: At week 16 of treatment.

  21. Triglycerides

    Mean difference between groups in Triglycerides

    Time frame: At week 16 of treatment.

  22. TG-glucose index

    Mean difference between groups in TG-glucose index

    Time frame: At week 16 of treatment.

  23. Systolic blood pressure

    Mean difference between groups in systolic blood pressure

    Time frame: At week 16 of treatment.

  24. Diastolic blood pressure

    Mean difference between groups in diastolic blood pressure

    Time frame: At week 16 of treatment.

  25. Albumin to Creatinine Ratio

    Mean difference between groups in Albumin to Creatinine Ratio

    Time frame: At week 16 of treatment.

  26. Hepatic Steatosis Index (HSI)

    Mean difference between groups in HSI

    Time frame: At week 16 of treatment.

  27. Fibrosis Score (FIB-4)

    Mean difference between groups in FIB-4

    Time frame: At week 16 of treatment.

07

Study locations

3 of 3 sites recruiting
  • DiaCenTRE - Hirslanden Clinique des Grangettes
    Chêne-Bougeries, Canton of Geneva 1224, Switzerland
    Recruiting
    • Giacomo Gastaldi, PD Dr. med · Contactgiacomo.gastaldi@diacentre.ch · +41 22 705 11 88
    • Giacomo Gastaldi, PD Dr. med. · Principal investigator
  • Kantonsspital Olten
    Olten, Canton of Solothurn 4600, Switzerland
    Recruiting
  • Luzerner Kantonspital
    Lucerne, 6000, Switzerland
    Recruiting
    • Gabriella Gallo · Contactgabriela.gallo@luks.ch · +41412056192
    • Stephan Fischli, PD Dr. med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2026, 16 months after the start.

Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2024
First posted
Oct 8, 2024
StartActual
Feb 14, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630585
Lead sponsor
University of Bern
Collaborators
Kantonsspital Olten, Luzerner Kantonsspital, Clinique des Grangettes, Chêne-Bougeries
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Feb 14, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Jose F Garcia-Tirado, PhD
Contact
jose.garcia@unibe.ch
+41316646109
Marie-Aline Gerard, MSc
Contact
marie-aline.gerard@dcberne.com
+41782049811
Thomas Zueger, PD Dr. med.
principal investigator · Kantonsspital Olten

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion